MSC-derived exosome therapy for endothelial dysfunction in postpartum mothers with prior preeclampsia
Preeclampsia · Endothelial Injury
Enrolment: 80 · Results not recorded
Loading the evidence…
Biologic · Cell-derived extracellular vesicle product; no ChEMBL entity by nature. Trials listed are human MSC-derived exosome/EV products; NCT05354141 (ExoFlo, bone-marrow MSC EV) is the closest match to the source therapy. Only interventional studies of the EV product itself were retained.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Preeclampsia · Endothelial Injury
Enrolment: 80 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 970 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 50 · Results not recorded
Cerebrovascular Disorders
Enrolment: 5 · Results not recorded
Perianal Fistula in Crohn's Disease
Enrolment: 80 · Results not recorded
Type 2 Diabetes Mellitus
Enrolment: 66 · Results not recorded
Alveolar Bone Loss · Bone Regeneration
Enrolment: 40 · Results not recorded
Anti Aging
Enrolment: 20 · Results not recorded
Syringomyelia
Enrolment: 18 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute soft tissue injury induced by a strike (contusion) model
Exosomes of approximately 100 nm were isolated from rat bone marrow mesenchymal stem cells and characterised by nanoparticle tracking, electron microscopy and Western blot. Severe soft tissue inflammation in the strike group was alleviated by both stem cell and exosome treatment. Exosome treatment…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.